In order to succeed, biotech, drug, and device companies must publish their results in peer-reviewed journals in an effort to add value to promote and commercialize their technologies. The drivers of this exercise include reimbursement, credibility, commercialization and valuations. If you’re not publishing, you’re missing out on valuable opportunities to improve the chances for your company to succeed.
In this interactive program, you will learn the how, why and when of a successful publication strategy. Experts in the field will be joined by professionals who have effectively implemented the process. You will learn from their successes and failures. Join Johnson & Johnson Innovation, JLABS (JLABS) and Janssen Healthcare Innovation as we showcase three local companies that are disrupting the healthcare space with one common thread – putting the patient at the center of care. We’ll explore topics including:
- When, where and what to publish
- Timing of publications throughout the product development cycle
- Article types to consider, and why; look at both home runs and base hits
- How peer-reviewed publications support reimbursement strategy
- Developing a roadmap to maximize publication objectives
- PR and your publication program
The program will include case examples and a sample roadmap for success.
Tom Albright | Chairman & CEO, Andrew Technologies read bio»
Joel Batts, MA | Partner, Telos Partners, LLC read bio»
Peter Burks Ph. D. | CEO, ActiveLife Scientific read bio»
Heidi Chokeir, Ph.D. | Senior Vice President, Canale Communications read bio»
3:30 PM | Registration Opens, Networking Lunch
4:00 PM | Presentations and Q&A
5:00 PM | Panel Discussion and Q&A
5:45 PM | Light Hors D'Oeuvres and Networking
7:00 PM | Program Close
$25 | General Public
$15 | Student/Academic
$35 | At the door
3210 Merryfield Row
San Diego, CA
Tom Albright | Chairman of the Board and CEO, Andrew Technologies LLC
Tom has over 30 years of experience in the field of pharmaceutical, biologic, device and aesthetic-related sales, marketing and general management roles. He joined the Company in June 2011 as CEO. Prior to that, he was president of the topical aesthetic division at Syneron Medical Ltd. from 2010 to 2011. From 2008 to 2010, he was head of North American marketing at Nobel Biocare, a leading dental aesthetics company. His medical aesthetic experience commenced with Allergan (2000 – 2008), where he led the launch of BOTOX® Cosmetic and the commercial development of Latisse®. He was also the alliance manager for the collaboration between Allergan and GlaxoSmithKline in China, Japan, and the US. In 1983, he commenced his career in healthcare with the Parke-Davis division of Warner Lambert, where he held sales and marketing leadership roles, including the 1997 launch of Lipitor®, among other brands. Tom is also a Board member of Bonti Inc. Tom has a BS in biology from The Citadel and an MBA in marketing from Mercer University.
Connect with Tom:
Joel Batts, MA | Partner, Telos Partners, LLC
Joel is a medical device industry veteran, with 20 years of leadership experience developing scientific and regulatory strategies for start-ups to large cap companies. He has delivered >$100 million return on investment by delivering FDA approvals for Class II and Class III devices in the musculoskeletal and wound care spaces. He has published and presented the results of pre-clinical and clinical science in journals such as American Journal of Sports Medicine, American Journal of Orthopaedics, and venues such as the American College of Foot and Ankle Surgeons. In 2010, he led a business development team in the application of a novel biologic material to osteoporotic patients for reducing the incidence of hip fractures. After conducting early-phase trials and developing the scientific and regulatory, the team sold the technology for $30 million. He has also overseen key areas of investment and integration for four major acquisitions. Outside of Telos Partners, Joel is part of a LifeNet International, a non-profit that is transforming healthcare in African communities. Joel earned a BS in exercise science from the University of Florida and an MA in bioethics and health policy from Loyola University Chicago.
Connect with Joel:
Peter Burks, Ph. D. | CEO, ActiveLife Scientific
Dr. Burks began his career in a research laboratory at UC Santa Barbara, where he earned his PhD in Chemistry under the guidance of Prof. Peter C. Ford. After graduation, Peter’s passion for turning laboratory science into products that improve people’s lives led him to find ActiveLife.
Since joining the team in 2014, Peter has played an integral leadership role across nearly all functions of the company. He began in sales lead generation and market education, but quickly ascended to become the head of sales and head of research support. Since late 2014, Peter has brought in over $1M in revenue while also working closely with ActiveLife’s customers and collaborators to facilitate their research success. During this period, publications using ActiveLife’s technology grew from less than 30 peer-reviewed articles to over 90. Peter’s timeline-driven management style and research skillset played a critical role in the commercialization of OsteoProbe for Research Use Only; he worked closely with the engineers to transition an academic laboratory prototype into a research instrument used by top institutions around the world. Recently, Peter has led efforts to map OsteoProbe’s regulatory pathway as well as explore initial commercialization applications. Since becoming CEO, Peter has emphasized strategic focus, team cohesiveness, and accountability. He works closely with the team to drive the company towards achieving the targeted regulatory and commercial goals.
During his PhD, Peter published 6 scientific articles and was recognized with several honors and awards including the Corning Inc. Foundation fellowship, multiple National Science Foundation fellowships, as well as a University Award of Distinction and the B.R. Baker Memorial Award, a top award in his program. While earning his PhD, he simultaneously participated in UCSB’s Technology Management Program where he earned a certificate in Entrepreneurship and was selected as the graduate commencement speaker.
Connect with Peter:
Heidi Chokeir | Senior Vice President, Canale Communications
Heidi Chokeir, Ph.D., is senior vice president at Canale Communications, a life science communications agency in San Diego. In addition to serving as a senior strategy lead, Heidi is CanaleComm’s unofficial chief scientific officer—always ready to dive deep into the science that makes each client unique.
Since joining CanaleComm in 2011, Heidi has put to use her background in science, innate storytelling skills and strategic thinking for clients ranging from the smallest of venture-backed biotech startups to the largest healthcare company in the world. She’s passionate about simplifying scientifically complex stories into messages that are compelling for audiences important to life science companies, including investors, potential partners and patients.
Heidi has planned and implemented award-winning public relations campaigns resulting in media coverage by outlets such as The New York Times, The Wall Street Journal, Bloomberg News, Fortune, IN VIVO, BioCentury, BioWorld Today and Biotech Nation. Prior to CanaleComm, Heidi served as account supervisor at Russo Partners, working primarily with early-stage biotech companies and research institutions.
She holds a Bachelor of Science in biochemistry with a minor in mathematics from Mount Saint Mary’s College in Los Angeles, and a Ph.D. in macromolecular and cellular structure and chemistry from The Scripps Research Institute in San Diego.
Connect with Heidi:
Save This Event
When & Where
JLABS San Diego
JLABS, part of Johnson & Johnson Innovation, LLC, is a network of life science incubators providing emerging companies many of the advantages of being in a big company, without the capital investment. JLABS offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Companies residing at JLABS also have access to core research labs hosting specialized capital equipment and shared administrative areas. JLABS is an open innovation model, and the agreement for space does not grant JLABS or Johnson & Johnson Innovation any stake or rights in the companies, nor will the companies have a guaranteed future affiliation with JLABS. The flagship facility is located in San Diego at Janssen's West Coast Research Center, and JLABS has now two established locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility - one in Boston through a collaboration with Lab Central, one in Houston through a collaboration with TMC, and one in Toronto through a collaboration with MaRS. For more information please visit jlabs.jnjinnovation.com.